Sonnet BioTherapeutics Highlights Safety Profile For Lead Cancer Candidate
- Sonnet BioTherapeutics Holdings Inc says that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 trials.
- The adverse events have generally been mild/moderate, transient in nature, and have all been tolerable. In addition, they have been less numerous and less intense with subsequent doses.
- There was minimal/no signal for IL-1β, IL-6, IL-8, or TNFα and no indication of cytokine release syndrome (CRS). IL-10 was also induced at a low level, as expected.
- Five of the six patients had stable disease at the first follow-up scan, with one patient progressing who is now off study. Investors are may be reacting to this.
- As of the most recent scan, 2 of the five stable disease patients remain stable, while the others had tumor growth that may represent tumor inflammation or unconfirmed progression.
- One endometrial stromal sarcoma patient progressing at study entry has evidence of improvement after six months on SON-1010 with smaller tumors and complete resolution of ascites.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.